Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

ConclusionPreclinical assessments suggested a low likelihood of immunogenicity for tralokinumab. In STRATOS  1 and 2, ADA incidence was low, no differences were found between tralokinumab-treated and placebo groups in reporting of hypersensitivity reactions, and there were no Sampson criteria-evaluated anaphylaxis events with tralokinumab treatment. Together, the results suggest that tralokinumab treatme nt would not increase the risk for severe hypersensitivity or anaphylactic reactions.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research